Hims & Hers Health (HIMS) Long-Term Investments (2019 - 2025)

Hims & Hers Health (HIMS) reported Long-Term Investments of $351.3 million for Q4 2025, down 19.87% sequentially from $438.3 million in Q3 2025.

Hims & Hers Health (HIMS) Long-Term Investments (2019 - 2025) Analysis & Trends

Hims & Hers Health (HIMS) has 3 years of Long-Term Investments data on file, last reported at $351.3 million in Q4 2025.

For the quarter ending Q4 2025, Long-Term Investments changed N/A year-over-year to $351.3 million; the trailing twelve-month figure through Dec 2025 stood at $351.3 million (changed N/A YoY), and the FY2025 full-year result was $351.3 million, changed N/A from the prior year.
Long-Term Investments fell to $351.3 million in Q4 2025, from $438.3 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $438.3 million in Q3 2025 to a low of $351.3 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Haleon	88.07 Bn	86.20 Bn	-	-
2	Teva Pharmaceutical Industries	35.75 Bn	32.01 Bn	1.97 Bn	-
3	Zoetis	31.84 Bn	29.90 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	27.18 Bn	23.12 Bn	4.39 Bn	56.09 Mn
5	United Therapeutics	23.09 Bn	20.93 Bn	648.10 Mn	1.32 Bn
6	RedHill Biopharma	21.32 Bn	21.32 Bn	-	12.05 Mn
7	Viatris	19.96 Bn	18.16 Bn	1.16 Bn	-
8	Neurocrine Biosciences	17.66 Bn	16.34 Bn	800.70 Mn	146.10 Mn
9	Elanco Animal Health	12.44 Bn	12.02 Bn	785.00 Mn	-
10	Hims & Hers Health	6.44 Bn	5.69 Bn	396.79 Mn	-

Download Data